Načítá se...
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients
BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal models of Parkinson’s disease (PD). Effects of rhPDGF-BB are the result of proliferation of ventricular wall progenitor cells and reversed by blocking mi...
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4362250/ https://ncbi.nlm.nih.gov/pubmed/25689258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI79635 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|